22nd Century Group (XXII) 2013年年度报告「NYSE」.pdf

1、Stock Ticker:XXIIStock Ticker:XXII22nd Century Group,Inc.9530 Main StreetClarence,New York 14031Telephone:(716)270-1523Fax:(716)877- 22nd Century Group,Inc.22nd Century Group,Inc.2013 ANNUAL REPORT2013 ANNUAL REPORT2013 Annual Report Cover 3.indd 12/28/14 5:56 PMDear Fellow Shareholders:Even though

2、our last shareholders meeting was less than six months ago,22nd Century Group has made quite a transformation since that perfect,sunny September day.First,we closed on the long awaited international licensing deal with British American Tobacco which generated$7 million in revenue to the Company.Seco

3、nd,we acquired a turnkey manufacturing facility in Mocksville,North Carolina from a bankruptcy estate for pennies on the dollar.Also in the fourth quarter of 2014,as a subcontractor under a government contract,the Company sold the U.S.Food and Drug Administration(“FDA”)$225,883 of our proprietary VL

4、N tobacco.We closed the year with a successful warrant exchange that,as of December 12,2013,eliminated over 90%of our warrant liability and generated gross proceeds of approximately$3.6 million for the Company,thereby paving the way for the Companys stock to be uplisted to a national securities exch

5、ange.22nd Century Group was cash flow positive in 2013.The Company recorded operating income of$1.8 million for 2013,compared to an operating loss of$3.2 million for 2012.As reported on January 30,2014,adjusted EBITDA was$4.3 million,or$0.10 per diluted common share for 2013,compared to adjusted EBI

6、TDA of negative$1.8 million,or($0.06)per diluted common share for 2012.As a result of these and other events,22nd Century Groups share price increased 185%in 2013,as compared to an increase of 78%in 2012.From a more qualitative perspective,the Company also made tremendous progress.In 2013,The Center